Artelo Biosciences, Inc. has entered into a global research and development partnership with Syngene International Ltd. (Syngene), an India-based integrated discovery-development service provider. The partnership will focus on supporting the drug discovery and clinical development of ART27.13, Artelo’s Phase 2 ready, high-potency dual cannabinoid agonist, in oncology.    “ART27.13 represents an important new therapeutic class of anti-cancer medicine. While a lot is already kn...